🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →
S&P 500: 759.97 -0.5% NASDAQ 100: 704.40 0.0% Dow Jones: 534.08 -0.5%

Merck & Co - Q4 2025 13F Filings

ME

Merck & Co., Inc.

CIK: 0000310158
Address: New Jersey Rahway 126 East Lincoln Avenue P.O. Box 2000
$276.28 M
Portfolio Value
12
Assets Held
Reporting Period: Q4 2025
Filing Status:
Active
Last Updated: 08/07/2026

Portfolio Summary (Q4 2025)

View Full Portfolio Analysis

Top Buys

Q4 2025

No buy transactions available for this period

Top Sells

Q4 2025
1. LVTX Lava Therapeutics Nv
−$1.79 M

Asset Allocation

Stocks/ETFs
+21.04%
$270.49 M 97.90%
Options
$0 0.00%
Debt
$0 0.00%
Other
+26.86%
$5.79 M 2.10%

Sector Allocation (Stocks)

Merck & Co Q4 2025 Filing Summary

Merck & Co., Inc. filed its 13F report for Q4 2025 on February 17, 2026. The portfolio totaled 276.28 M reflecting a +21.16% change from the prior quarter, spanning 12 assets. The top 10 holdings comprised 100.0% of the portfolio, with Financials as the largest sector allocation. Quarterly activity included 0 new positions and 1 complete exits.

Report Type

Status

Data Summary

Items:

Total Value:

Actions

Issuer Name Class Value Shares Option Type

FAQs for Merck & Co’s Q4 2025 Filing

Merck & Co submitted their Form 13F-HR for the Q4 2025 period on 02/17/2026. This was the only submission for the quarter.

In the Q4 2025 filing, Merck & Co reported a managed portfolio value of 276.28 M, consisting of 12 individual positions.

This page displays the raw filing documents. To see which stocks Merck & Co bought or sold during Q4 2025, please visit Merck & Co's Portfolio Analysis page.